EDAP Expands Product Portfolio With New Urological Stone Lasers
2015年2月26日 - 10:30PM
EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic
ultrasound, today announced a multi-national strategic OEM
partnership with Quanta System, a leading manufacturer of medical
lasers for surgical and other applications. Under the agreement,
Quanta will manufacture customized urological stone lasers to be
sold under the EDAP brand. Additionally, EDAP will continue to
distribute Holmium lasers in France and certain North African
territories, pursuant to its exclusive agreement with Lumenis in
those regions.
Marc Oczachowski, EDAP's Chief Executive Officer, commented,
"The addition of urological stone lasers to EDAP's product
portfolio will provide excellent synergy with our existing
lithotripsy offering for the treatment of urinary stones. We are
excited to partner with Quanta System, the world leader in
development and manufacture of stone lasers to bring their
cutting-edge technology to urologists and patients and drive
incremental growth for our Company. This strategic partnership
enables EDAP to offer a complete range of minimally invasive
solutions from intracorporeal lithotripsy lasers to extracorporeal
shockwave lithotripsy devices, covering the full scope of urinary
tract stone indications."
Oczachowski continued: "With our well-established, worldwide
network of fully-owned subsidiaries, dedicated distributors and
partners, we are well positioned to maximize our lithotripsy sales
activity going forward."
Paolo Salvadeo, Quanta System's Chief Executive Officer,
commented: "We are very happy to partner with EDAP as this new
cooperation strengthens our position in the worldwide urology
market, where Quanta already enjoys strong market share in laser
lithotripsy. Our core solutions for urinary stones represent a real
benchmark for the industry, and we are pleased to offer them to
EDAP, a dynamic company that shares many similarities with Quanta,
and to contribute to their continued success throughout the
world."
About EDAP TMS SA
EDAP TMS SA markets today Ablatherm® for high-intensity focused
ultrasound (HIFU) treatment of localized prostate cancer. HIFU
treatment is shown to be a minimally invasive and effective
treatment option with a low occurrence of side effects.
Ablatherm-HIFU is generally recommended for patients with localized
prostate cancer (stages T1-T2) who are not candidates for surgery
or who prefer an alternative option, or for patients who failed
radiotherapy treatment, Ablatherm-HIFU is approved and
commercialized in Europe as a treatment for prostate cancer and is
currently under regulatory review in the U.S. following submission
of the Pre-Market Approval Application in February 2013 after the
completion of a multi-center U.S. Phase II/III clinical trial
under an Investigational Device Exemption (IDE) granted by the FDA.
In March 2013, the Company introduced a new innovative HIFU device,
the Focal One® dedicated to focal therapy of prostate cancer. Focal
One® is CE marked but is not FDA approved. The Company also
develops its HIFU technology for the potential treatment of certain
other types of tumors. EDAP TMS SA also produces and commercializes
medical equipment (the Sonolith® range) for treatment of urinary
tract stones using extra-corporeal shockwave lithotripsy (ESWL).
For more information on the Company, please visit
http://www.edap-tms.com, and http://www.hifu-planet.com.
About Quanta System S.p.A.
Quanta System S.p.A produces lasers and laser systems for a wide
range of scientific, medical and industrial applications. Quanta
System S.p.A. was founded in 1985. Today, with over twenty years of
experience in the design of laser sources, laser systems and
specific solutions for the OEM market, it is a global company
founded on a myriad of local expertise: Italian creativity and
research, the methodology and tradition of the German optics
industry, American-style Oriented Marketing, and the successful
Spanish distribution model. For more information on Quanta System,
please visit http://www.quantasystem.com.
Forward-Looking Statements
In addition to historical information, this press release may
contain forward-looking statements. Such statements are based on
management's current expectations and are subject to a number of
risks and uncertainties, including matters not yet known to us or
not currently considered material by us, and there can be no
assurance that anticipated events will occur or that the objectives
set out will actually be achieved. Important factors that could
cause actual results to differ materially from the results
anticipated in the forward-looking statements include, among others
the uncertainties of the U.S. FDA approval process, the clinical
status and market acceptance of our HIFU devices and the
continued market potential for our lithotripsy device. Factors that
may cause such a difference also may include, but are not limited
to, those described in the Company's filings with the Securities
and Exchange Commission and in particular, in the sections
"Cautionary Statement on Forward-Looking Information" and "Risk
Factors" in the Company's Annual Report on Form 20-F.
Ablatherm-HIFU treatment is in clinical trials, but not
FDA-approved or marketed in the United States.
CONTACT: Blandine Confort
Investor Relations / Legal Affairs
EDAP TMS SA
+33 4 72 15 31 72
bconfort@edap-tms.com
Investors:
Lee Roth
The Ruth Group
646-536-7012
lroth@theruthgroup.com
EDAP TMS (NASDAQ:EDAP)
過去 株価チャート
から 6 2024 まで 7 2024
EDAP TMS (NASDAQ:EDAP)
過去 株価チャート
から 7 2023 まで 7 2024